Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources
- PMID: 8607595
- DOI: 10.7326/0003-4819-124-7-199604010-00007
Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources
Abstract
Objectives: 1) To determine the proportions of patients with visceral leishmaniasis who had various treatment outcomes when cared for under wartime conditions and with limited resources and 2) to identify patient characteristics associated with the outcomes.
Design: Cohort study.
Setting: Médecins sans Frontières-Holland's treatment center in Duar, Western Upper Nile Province, an area in southern Sudan that has been severely affected by Sudan's civil war and a massive epidemic of visceral leishmaniasis.
Patients: 3076 consecutive patients who had visceral leishmaniasis, were admitted to the treatment center the first year the center was operational (August 1990 to July 1991), and were treated with the pentavalent antimonial compound sodium stibogluconate.
Measurements: Patient characteristics on admission and four mutually exclusive treatment outcomes (default during first admission, death during first admission, discharge and readmission for retreatment [relapse], and discharge and no readmission for retreatment [successful treatment]).
Results: The patients had a median age of 15 years and were notably anemic (median hemoglobin level, 77g/L) and malnourished (median body mass index of adults [> or = 18 years of age], 15.2 kg/m2); most (91.0%) had been sick less than 5 months. Although patients could not be monitored after treatment to document cure, most (2562 [83.3%]) were successfully treated; 336 (10.9%) died during their first admission, and 79 are known to have relapsed (3.0% of those discharged alive [that is, those whose final treatment outcome was successful treatment or relapse]). In univariable analysis, young and older age (<5 or > or = 45 years of age), long duration of illness (> or = 5 months), markedly low hemoglobin level or body mass index, large spleen, high parasite density, and vomiting at least once during the treatment course were associated with death. In multiple logistic regression analysis of data for a subgroup of 1207 adults (those who did not default or relapse and for whom data were recorded on age, sex, duration of illness, hemoglobin level, body mass index, and spleen size), the approximate risk ratios for death were 2.2 (95% Cl, 1.4 to 3.6) for those with a long duration of illness, 3.6 (Cl, 2.1 to 5.9) for those 45 years of age or older, 4.6 (Cl, 2.2 to 9.4) for those with a hemoglobin level less than 60 g/L, and 12.2 (Cl, 3.2 to 47.2) for those with a body mass index less than 12.2 kg/m2. CONCLUSION; Despite the severe debility of the patients and the exceptionally difficult circumstances under which they were treated, most fared remarkably well.
Comment in
-
Visceral leishmaniasis in southern Sudan.Ann Intern Med. 1997 Feb 15;126(4):332. doi: 10.7326/0003-4819-126-4-199702150-00018. Ann Intern Med. 1997. PMID: 9036811 No abstract available.
Similar articles
-
Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan.Clin Infect Dis. 2004 Mar 1;38(5):612-9. doi: 10.1086/381203. Epub 2004 Feb 12. Clin Infect Dis. 2004. PMID: 14986243
-
Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan.Trop Med Int Health. 2015 Dec;20(12):1674-84. doi: 10.1111/tmi.12603. Epub 2015 Nov 11. Trop Med Int Health. 2015. PMID: 26427033
-
Royal Society of Tropical Medicine and Hygiene joint meeting with Médecins Sans Frontières at Manson House, London, 20 March 2003: field research in humanitarian medical programmes. Médecins Sans Frontières interventions against kala-azar in the Sudan, 1989-2003.Trans R Soc Trop Med Hyg. 2003 Nov-Dec;97(6):609-13. doi: 10.1016/s0035-9203(03)80047-0. Trans R Soc Trop Med Hyg. 2003. PMID: 16134257
-
Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis.Infect Dis Poverty. 2018 Oct 19;7(1):108. doi: 10.1186/s40249-018-0491-7. Infect Dis Poverty. 2018. PMID: 30340519 Free PMC article.
-
[Treatment of visceral leishmaniasis in children].Med Trop (Mars). 2007 Feb;67(1):73-8. Med Trop (Mars). 2007. PMID: 17506279 Review. French.
Cited by
-
Rapid immunochromatographic strip test for detection of anti-K39 immunoglobulin G antibodies for diagnosis of visceral leishmaniasis.Clin Vaccine Immunol. 2008 Sep;15(9):1483-4. doi: 10.1128/CVI.00174-08. Epub 2008 Jul 16. Clin Vaccine Immunol. 2008. PMID: 18632926 Free PMC article.
-
High mortality among older patients treated with pentavalent antimonials for visceral leishmaniasis in East Africa and rationale for switch to liposomal amphotericin B.Antimicrob Agents Chemother. 2011 Jan;55(1):455-6. doi: 10.1128/AAC.01298-10. Epub 2010 Nov 15. Antimicrob Agents Chemother. 2011. PMID: 21078947 Free PMC article. No abstract available.
-
Parasite load and risk factors for poor outcome among children with visceral leishmaniasis. A cohort study in Belo Horizonte, Brazil, 2010-2011.Mem Inst Oswaldo Cruz. 2014 Apr;109(2):147-53. doi: 10.1590/0074-0276140257. Epub 2014 Mar 4. Mem Inst Oswaldo Cruz. 2014. PMID: 24676657 Free PMC article.
-
Species-directed therapy for leishmaniasis in returning travellers: a comprehensive guide.PLoS Negl Trop Dis. 2014 May 1;8(5):e2832. doi: 10.1371/journal.pntd.0002832. eCollection 2014 May. PLoS Negl Trop Dis. 2014. PMID: 24787001 Free PMC article.
-
Ecology of cutaneous leishmaniasis in Sinai: linking parasites, vectors and hosts.Mem Inst Oswaldo Cruz. 2014 Jun;109(3):299-306. doi: 10.1590/0074-0276130426. Epub 2014 May 7. Mem Inst Oswaldo Cruz. 2014. PMID: 24821060 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources